Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23405247 | 0.86 | SNCA (0.39) | JAK2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL7965037 | 0.83 | CYP3A4 (0.44) | CYP2C9CYP3A4CYP2C19CYP2D6KDM4E | |
| SCHEMBL19710201 | 0.82 | JAK2 (0.50) | JAK2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL14197017 | 0.81 | CYP2D6 (0.43) | CYP3A4CYP2C19CYP2D6KDM4EMEN1 | |
| SCHEMBL30275071 | 0.81 | CYP2D6 (0.43) | CYP2C9CYP3A4CYP2C19CYP2D6KDM4E | |
| SCHEMBL30068918 | 0.81 | AURKA (0.47) | JAK2CYP3A4CYP2C19CYP2D6KDM4E | |
| SCHEMBL857144 | 0.81 | AURKA (0.47) | JAK2CYP3A4CYP2C19CYP2D6KDM4E | |
| SCHEMBL27787175 | 0.80 | JAK2 (0.51) | JAK2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| Iodide SCHEMBL30068502 | 0.80 | AURKA (0.46) | JAK2CYP3A4CYP2C19CYP2D6KDM4E | |
| Iodide SCHEMBL25299428 | 0.80 | AURKA (0.46) | JAK2CYP3A4CYP2C19CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2025-06-26 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| EP-3836919-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | Recreo Pharmaceuticals Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-05-13 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| CN-101605787-A | Compounds that modulate c-fms and/or c-kit activity and uses thereof | PLEXXIKON INC (US) | 2009-12-16 | — | — | CN | disclosed |
| EP-2086972-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063888-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | CBR3, CBR1, CYP2B6 | JAK2 2873/4885CYP2C9 390/4885CYP3A4 555/4885 |
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | JAK2 1155/4885CYP2C9 3125/4885CYP3A4 2188/4885 |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | JAK2 108/4885CYP2C9 4122/4885CYP3A4 3847/4885 |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | JAK2 1155/4885CYP2C9 3125/4885CYP3A4 2188/4885 |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA1, FOXM1 | JAK2 2242/4885CYP2C9 1191/4885CYP3A4 1217/4885 |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | JAK2 1155/4885CYP2C9 3125/4885CYP3A4 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.